메뉴 건너뛰기




Volumn 95, Issue 11, 2016, Pages 1751-1756

Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura

Author keywords

Bortezomib; Refractory; Relapsed; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR;

EID: 84984923647     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2804-x     Document Type: Review
Times cited : (36)

References (38)
  • 1
    • 84937806975 scopus 로고    scopus 로고
    • Treatment and outcome of primary and secondary thrombotic microangiopathies
    • PID: 26183157
    • Eskazan AE, Salihoglu A (2015) Treatment and outcome of primary and secondary thrombotic microangiopathies. Am J Nephrol 41(6):427–428
    • (2015) Am J Nephrol , vol.41 , Issue.6 , pp. 427-428
    • Eskazan, A.E.1    Salihoglu, A.2
  • 2
    • 0034099646 scopus 로고    scopus 로고
    • Management of thrombotic thrombocytopenic purpura
    • COI: 1:STN:280:DC%2BD3czksFequw%3D%3D, PID: 10886194
    • Rock GA (2000) Management of thrombotic thrombocytopenic purpura. Br J Haematol 109(3):496–507
    • (2000) Br J Haematol , vol.109 , Issue.3 , pp. 496-507
    • Rock, G.A.1
  • 3
    • 84929994371 scopus 로고    scopus 로고
    • How I treat refractory thrombotic thrombocytopenic purpura
    • COI: 1:CAS:528:DC%2BC2MXhtFCmsb%2FF, PID: 25784681
    • Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125(25):3860–3867
    • (2015) Blood , vol.125 , Issue.25 , pp. 3860-3867
    • Sayani, F.A.1    Abrams, C.S.2
  • 4
    • 84871810864 scopus 로고    scopus 로고
    • ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura
    • COI: 1:CAS:528:DC%2BC3sXlvFahsw%3D%3D, PID: 23281998
    • Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368(1):90–92
    • (2013) N Engl J Med , vol.368 , Issue.1 , pp. 90-92
    • Shortt, J.1    Oh, D.H.2    Opat, S.S.3
  • 5
    • 84906225926 scopus 로고    scopus 로고
    • Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report
    • PID: 24655327
    • Yates S, Matevosyan K, Rutherford C et al (2014) Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 54(8):2064–2067
    • (2014) Transfusion , vol.54 , Issue.8 , pp. 2064-2067
    • Yates, S.1    Matevosyan, K.2    Rutherford, C.3
  • 6
    • 84896697168 scopus 로고    scopus 로고
    • Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura
    • COI: 1:CAS:528:DC%2BC2cXjslWmurY%3D, PID: 24345005
    • Mazepa MA, Raval JS, Moll S et al (2014) Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 164(6):900–902
    • (2014) Br J Haematol , vol.164 , Issue.6 , pp. 900-902
    • Mazepa, M.A.1    Raval, J.S.2    Moll, S.3
  • 7
    • 84890200058 scopus 로고    scopus 로고
    • Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib
    • PID: 24118335
    • van Balen T, Schreuder MF, de Jong H et al (2014) Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 92(1):80–82
    • (2014) Eur J Haematol , vol.92 , Issue.1 , pp. 80-82
    • van Balen, T.1    Schreuder, M.F.2    de Jong, H.3
  • 8
    • 84963603723 scopus 로고    scopus 로고
    • Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib
    • Patel PP, Becker J, Freyer C et al (2016) Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion. doi:10.1111/trf.13465
    • (2016) Transfusion
    • Patel, P.P.1    Becker, J.2    Freyer, C.3
  • 9
    • 84974814364 scopus 로고    scopus 로고
    • Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura
    • PID: 27284100
    • Acedillo RR, Govind M, Kashgary A et al (2016) Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura. BMJ Case Rep. doi:10.1136/bcr-2016-215491
    • (2016) BMJ Case Rep
    • Acedillo, R.R.1    Govind, M.2    Kashgary, A.3
  • 10
    • 84961802012 scopus 로고    scopus 로고
    • Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura
    • PID: 27009919
    • Patriquin CJ, Thomas MR, Dutt T et al (2016) Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. doi:10.1111/bjh.13993
    • (2016) Br J Haematol
    • Patriquin, C.J.1    Thomas, M.R.2    Dutt, T.3
  • 11
    • 38349159575 scopus 로고    scopus 로고
    • Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006
    • COI: 1:CAS:528:DC%2BD1cXjtlyhtbY%3D, PID: 18028271
    • Nguyen L, Li X, Duvall D et al (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 48(2):349–357
    • (2008) Transfusion , vol.48 , Issue.2 , pp. 349-357
    • Nguyen, L.1    Li, X.2    Duvall, D.3
  • 12
    • 0025999820 scopus 로고
    • Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients
    • COI: 1:STN:280:DyaK3M3oslOnuw%3D%3D, PID: 2062331
    • Bell WR, Braine HG, Ness PM et al (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325(6):398–403
    • (1991) N Engl J Med , vol.325 , Issue.6 , pp. 398-403
    • Bell, W.R.1    Braine, H.G.2    Ness, P.M.3
  • 13
    • 77951650730 scopus 로고    scopus 로고
    • Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study
    • COI: 1:CAS:528:DC%2BC3cXkvVCqu7w%3D, PID: 20033409
    • Balduini CL, Gugliotta L, Luppi M et al (2010) Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89(6):591–596
    • (2010) Ann Hematol , vol.89 , Issue.6 , pp. 591-596
    • Balduini, C.L.1    Gugliotta, L.2    Luppi, M.3
  • 14
    • 84925010068 scopus 로고    scopus 로고
    • The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura
    • COI: 1:CAS:528:DC%2BC2MXkvVCgu7c%3D, PID: 25573992
    • Lim W, Vesely SK, George JN (2015) The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 125(10):1526–1531
    • (2015) Blood , vol.125 , Issue.10 , pp. 1526-1531
    • Lim, W.1    Vesely, S.K.2    George, J.N.3
  • 15
    • 84989233357 scopus 로고    scopus 로고
    • The efficacy of vincristine in the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura
    • [abstract]
    • Ongoren Aydin S, Sadri S, Apaydin T et al (2014) The efficacy of vincristine in the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Haematologica 99(s1):474 [abstract]
    • (2014) Haematologica , vol.99 , Issue.s1 , pp. 474
    • Ongoren Aydin, S.1    Sadri, S.2    Apaydin, T.3
  • 16
    • 84869161774 scopus 로고    scopus 로고
    • Thrombotic microangiopathies reference center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience
    • PID: 22404639
    • Beloncle F, Buffet M, Coindre J-P et al (2012) Thrombotic microangiopathies reference center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience. Transfusion 52(11):2436–2444
    • (2012) Transfusion , vol.52 , Issue.11 , pp. 2436-2444
    • Beloncle, F.1    Buffet, M.2    Coindre, J.-P.3
  • 17
    • 84880229426 scopus 로고    scopus 로고
    • Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature
    • PID: 23121663
    • Yilmaz M, Eskazan AE, Unsal A et al (2013) Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion 53(7):1586–1593
    • (2013) Transfusion , vol.53 , Issue.7 , pp. 1586-1593
    • Yilmaz, M.1    Eskazan, A.E.2    Unsal, A.3
  • 18
    • 27244460395 scopus 로고    scopus 로고
    • Splenectomy for the treatment of thrombotic thrombocytopenic purpura
    • COI: 1:STN:280:DC%2BD2MvkvVGksQ%3D%3D, PID: 16115135
    • Kappers-Klunne MC, Wijermans P, Fijnheer R et al (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 130(5):768–776
    • (2005) Br J Haematol , vol.130 , Issue.5 , pp. 768-776
    • Kappers-Klunne, M.C.1    Wijermans, P.2    Fijnheer, R.3
  • 19
    • 84892481567 scopus 로고    scopus 로고
    • Cancer Care Ontario Hematology Disease Site Group. Bortezomib in multiple myeloma: a practice guideline
    • COI: 1:STN:280:DC%2BC2c3kslOlsA%3D%3D
    • Kouroukis CT, Baldassarre FG, Haynes AE et al (2014) Cancer Care Ontario Hematology Disease Site Group. Bortezomib in multiple myeloma: a practice guideline. Clin Oncol (R Coll Radiol) 26(2):110–119
    • (2014) Clin Oncol (R Coll Radiol) , vol.26 , Issue.2 , pp. 110-119
    • Kouroukis, C.T.1    Baldassarre, F.G.2    Haynes, A.E.3
  • 20
    • 67650462779 scopus 로고    scopus 로고
    • Clinical development of novel proteasome inhibitors for cancer treatment
    • COI: 1:CAS:528:DC%2BD1MXns1eru7s%3D, PID: 19505187
    • Yang H, Zonder JA, Dou QP (2009) Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 18(7):957–971
    • (2009) Expert Opin Investig Drugs , vol.18 , Issue.7 , pp. 957-971
    • Yang, H.1    Zonder, J.A.2    Dou, Q.P.3
  • 21
    • 84907966802 scopus 로고    scopus 로고
    • Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management
    • Vincent RS (2014) Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(10):999–1009
    • (2014) Am J Hematol , vol.89 , Issue.10 , pp. 999-1009
    • Vincent, R.S.1
  • 23
    • 84947125878 scopus 로고    scopus 로고
    • Bortezomib in kidney transplantation
    • COI: 1:CAS:528:DC%2BC2MXhvVarsbjF, PID: 26536428
    • Shah N, Meouchy J, Qazi Y (2015) Bortezomib in kidney transplantation. Curr Opin Organ Transplant 20(6):652–656
    • (2015) Curr Opin Organ Transplant , vol.20 , Issue.6 , pp. 652-656
    • Shah, N.1    Meouchy, J.2    Qazi, Y.3
  • 24
    • 84865593513 scopus 로고    scopus 로고
    • Bortezomib for acute antibody-mediated rejection in liver transplantation
    • COI: 1:CAS:528:DC%2BC38XhsVyrurvK, PID: 22681986
    • Paterno F, Shiller M, Tillery G et al (2012) Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 12(9):2526–2531
    • (2012) Am J Transplant , vol.12 , Issue.9 , pp. 2526-2531
    • Paterno, F.1    Shiller, M.2    Tillery, G.3
  • 25
    • 77952817334 scopus 로고    scopus 로고
    • Management of treatment-related adverse events in patients with multiple myeloma
    • PID: 20472185
    • Mateos MV (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 36(Suppl 2):S24–S32
    • (2010) Cancer Treat Rev , vol.36 , pp. S24-S32
    • Mateos, M.V.1
  • 26
    • 84993814033 scopus 로고    scopus 로고
    • Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma
    • COI: 1:CAS:528:DC%2BC38XosFSis74%3D, PID: 23556118
    • Mateos MV, San Miguel JF (2012) Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3(2):117–124
    • (2012) Ther Adv Hematol , vol.3 , Issue.2 , pp. 117-124
    • Mateos, M.V.1    San Miguel, J.F.2
  • 27
    • 30344470197 scopus 로고    scopus 로고
    • Drug-induced thrombotic microangiopathy
    • COI: 1:CAS:528:DC%2BD28XptlSgug%3D%3D, PID: 16388419
    • Zakarija A, Bennett C (2005) Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31(6):681–690
    • (2005) Semin Thromb Hemost , vol.31 , Issue.6 , pp. 681-690
    • Zakarija, A.1    Bennett, C.2
  • 28
    • 56649121992 scopus 로고    scopus 로고
    • Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma
    • PID: 18636313
    • Morita R, Hashino S, Shirai S et al (2008) Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 88(2):248–250
    • (2008) Int J Hematol , vol.88 , Issue.2 , pp. 248-250
    • Morita, R.1    Hashino, S.2    Shirai, S.3
  • 29
    • 84865448833 scopus 로고    scopus 로고
    • Bortezomib-induced thrombotic thrombocytopaenic purpura
    • Mehta N, Saxena A, Niesvizky R (2012) Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep vol.2012
    • (2012) BMJ Case Rep , vol.2012
    • Mehta, N.1    Saxena, A.2    Niesvizky, R.3
  • 30
    • 79955040869 scopus 로고    scopus 로고
    • Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib
    • COI: 1:CAS:528:DC%2BC3MXhs1Gqsb3O, PID: 21507163
    • Moore H, Romeril K (2011) Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 41(4):348–350
    • (2011) Intern Med J , vol.41 , Issue.4 , pp. 348-350
    • Moore, H.1    Romeril, K.2
  • 31
    • 84887211986 scopus 로고    scopus 로고
    • Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
    • PID: 22826795
    • Salmenniemi U, Remes K (2012) Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 4(2):e13
    • (2012) Hematol Rep , vol.4 , Issue.2
    • Salmenniemi, U.1    Remes, K.2
  • 32
    • 84983060381 scopus 로고    scopus 로고
    • Proteasome inhibitor associated thrombotic microangiopathy
    • PID: 27286661
    • Yui JC, Van Keer J, Weiss BM et al (2016) Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. doi:10.1002/ajh.24447
    • (2016) Am J Hematol
    • Yui, J.C.1    Van Keer, J.2    Weiss, B.M.3
  • 33
    • 84899046075 scopus 로고    scopus 로고
    • Bortezomib and heart failure: case-report and review of the French pharmacovigilance database
    • COI: 1:CAS:528:DC%2BC2cXmtFSgsL4%3D, PID: 23781941
    • Honton B, Despas F, Dumonteil N et al (2014) Bortezomib and heart failure: case-report and review of the French pharmacovigilance database. Fundam Clin Pharmacol 28(3):349–352
    • (2014) Fundam Clin Pharmacol , vol.28 , Issue.3 , pp. 349-352
    • Honton, B.1    Despas, F.2    Dumonteil, N.3
  • 34
    • 84875762528 scopus 로고    scopus 로고
    • Antibody depletion by bortezomib through blocking of antigen presentation
    • COI: 1:CAS:528:DC%2BC3sXls1aktbs%3D, PID: 23550684
    • Park SJ, Cheong HI, Shin JI (2013) Antibody depletion by bortezomib through blocking of antigen presentation. N Engl J Med 368(14):1364–1365
    • (2013) N Engl J Med , vol.368 , Issue.14 , pp. 1364-1365
    • Park, S.J.1    Cheong, H.I.2    Shin, J.I.3
  • 35
    • 33847662436 scopus 로고    scopus 로고
    • Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib
    • COI: 1:CAS:528:DC%2BD2sXislSrtLs%3D, PID: 17349869
    • Subklewe M, Sebelin-Wulf K, Beier C et al (2007) Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 68(3):147–155
    • (2007) Hum Immunol , vol.68 , Issue.3 , pp. 147-155
    • Subklewe, M.1    Sebelin-Wulf, K.2    Beier, C.3
  • 36
    • 84871025410 scopus 로고    scopus 로고
    • Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura
    • COI: 1:CAS:528:DC%2BC3sXht1Cqtbs%3D, PID: 22486316
    • Bhagirath VC, Kelton JG, Moore J et al (2012) Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion 52(12):2517–2523
    • (2012) Transfusion , vol.52 , Issue.12 , pp. 2517-2523
    • Bhagirath, V.C.1    Kelton, J.G.2    Moore, J.3
  • 37
    • 84904127650 scopus 로고    scopus 로고
    • French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
    • COI: 1:CAS:528:DC%2BC2cXht1WktbrO, PID: 24869941
    • Hie M, Gay J, Galicier L et al (2014) French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124(2):204–210
    • (2014) Blood , vol.124 , Issue.2 , pp. 204-210
    • Hie, M.1    Gay, J.2    Galicier, L.3
  • 38
    • 84865171981 scopus 로고    scopus 로고
    • Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
    • COI: 1:CAS:528:DC%2BC38XhsFertrfF, PID: 22802322
    • Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955
    • (2012) J Clin Oncol , vol.30 , Issue.24 , pp. 2946-2955
    • Sonneveld, P.1    Schmidt-Wolf, I.G.2    van der Holt, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.